<DOC>
	<DOC>NCT00293670</DOC>
	<brief_summary>To compare intermittent androgen deprivation (LHRHa treatment) with continuous androgen deprivation (LHRHa treatment or orchidectomy)</brief_summary>
	<brief_title>FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>• Inclusion Criteria (runin period): T1T4, metastatic (M1) prostate cancer T1T4, nonmetastatic (M0) prostate cancer with PSA &gt; 60 ng/mL T3T4, nonmetastatic (M0) prostate cancer with PSA &gt; 20ng/mL T1T4, N+ prostate cancer WHO performance status 02 Written informed consent • Inclusion criteria to the randomised period: Patients who fulfilled all entry criteria of the runin period Patients who completed the 24week runin period Patients who responded to the 24week runin period with a decrease of PSA to &lt; 10 ng/mL. If the baseline was &lt; 20ng/mL, at least 50% decrease from the baseline measurement is required Exclusion Criteria (runin period): Any previous or concurrent treatment of prostate cancer, except TURP, 5alpha reductase inhibitor, radical prostatectomy or radiotherapy Any medication/treatment affecting sex hormone status</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
</DOC>